Table 2.
The percentage of evaluated patients without ADT, GI and GU adverse effects, and their PSA concentrations during FU
| RT end | 1 month | 4 m. | 8 m. | 14 m. | 20 m. | 26 m. | |
|---|---|---|---|---|---|---|---|
| N of pts. | 200 | 142 | 167 | 149 | 117 | 48 | 18 |
| No ADT [%] | 46 | 66.2 | 76.1 | 81.2 | 86.3 | 85.4 | 94.1 |
| GI 0 [%] | 86.4 | 89.4 | 91.5 | 92.0 | 97.5 | 100.0 | 100.0 |
| GI 1 [%] | 13.1 | 8.5 | 6.7 | 7.3 | 2.5 | – | – |
| GI 2 [%] | 0.5 | 2.1 | 1.2 | 0.7 | – | – | – |
| GI 3 [%] | – | – | 0.6 | – | – | – | – |
| GU 0 [%] | 70.4 | 62.7 | 87.9 | 93.3 | 88.2 | 98.0 | 94.4 |
| GU 1 [%] | 20.1 | 32.4 | 10.3 | 6.0 | 8.4 | 2.0 | 5.6 |
| GU 2 [%] | 8.5 | 4.2 | 1.8 | 0.7 | 3.4 | – | – |
| GU 3 [%] | 1.0 | 0.7 | – | – | – | – | – |
| PSA range [ng/ml] | 0.008-15,2 | 0.008-16.3 | 0.02-5.7 | 0.00-6.4 | 0.002-6.7 | 0.008-6.3 | 0.01-10.0 |
| PSA mean | 4.1 | 2.1 | 1.1 | 0.7 | 0.5 | 0.5 | 0.9 |
| PSA median | 3.6 | 1.0 | 0.4 | 0.3 | 0.2 | 0.2 | 0.1 |
GI – gastrointestinal adverse effect (grade), GU – genitourinary adverse effect (grade), m – month, N – number, ADT – androgen deprivation therapy, RT – radiotherapy